SEC Form 4 · accession 0000899243-18-020447

CONSTELLATION PHARMACEUTICALS INC · CNST

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

10% Owner

Period of report

Jul 23, 2018

Accepted (ET)

Jul 23, 2018 · 8:04 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001434418

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Jul 23, 2018	C	174,926	—	A	174,926	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series E Preferred Stock^F1	—	Jul 23, 2018	C	444,444	D	—	—	Common Stock	51,905	D
Series E-1 Preferred Stock^F1	—	Jul 23, 2018	C	604,338	D	—	—	Common Stock	54,894	D
Series F Preferred Stock^F1	—	Jul 23, 2018	C	750,000	D	—	—	Common Stock	68,127	D

F1On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.